CORT · Company research
Corcept Therapeutics Inc. (CORT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
41records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? | Corcept Therapeutics reported Korlym sales of $373.5 million in H1 2026, up 6.2% year-over-year. The FDA approval of Lifyorli (relacorilant) in March 2026 generated $47.6 million in Q2 2026, marking the company's first quarter of commercial availability. The new drug aims to reduce CORT's dependence on Korlym. Relacorilant is also being studied in combination with other therapies for various cancers, with an FDA decision on the Cushing's syndrome indication expected by December 2026. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics | Zacks highlights five non-tech Nasdaq stocks with Zacks Rank #1 (Strong Buy) ratings positioned for Q4 gains. Ross Stores benefits from strong sales momentum and store expansion; Roku capitalizes on the shift from linear TV to streaming advertising; APA Corp offers favorable capital efficiency and long-term growth; Corcept Therapeutics sees strong demand for Korlym and new product launches; Halozyme benefits from collaboration royalties and milestone payments. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 1 | 1 |
| Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains | Despite the Nasdaq's tech-heavy composition, five non-tech Nasdaq-listed stocks with Zacks Rank #1 ratings are positioned for strong growth. Ross Stores plans 115 store openings with 13% Q2 sales growth, Roku's advertising revenue climbed 24.8%, APA Corp benefits from cost savings and long-term growth projects, Corcept Therapeutics sees strong drug demand with recent FDA approvals, and Halozyme generates royalties from pharma collaborations. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains | Despite the Nasdaq's tech-heavy composition, five non-tech Nasdaq-listed stocks with Zacks Rank #1 ratings are positioned for strong growth. Ross Stores plans 115 store openings with 13% Q2 sales growth, Roku's advertising revenue climbed 24.8%, APA Corp benefits from cost savings and long-term growth projects, Corcept Therapeutics sees strong drug demand with recent FDA approvals, and Halozyme generates royalties from pharma collaborations. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge | With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge | With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer | ImmunityBio received FDA approval to expand Anktiva's label for treating BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only disease. The approval, granted three months ahead of schedule, now covers all BCG-unresponsive NMIBC patients. Anktiva sales surged 121% year-over-year to $95 million in the first half of 2026, driven by strong physician adoption and new prescriber demand. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.667 | 1 |
| FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer | ImmunityBio received FDA approval to expand Anktiva's label for treating BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only disease. The approval, granted three months ahead of schedule, now covers all BCG-unresponsive NMIBC patients. Anktiva sales surged 121% year-over-year to $95 million in the first half of 2026, driven by strong physician adoption and new prescriber demand. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.667 | 1 |
| Here's Why You Should Add EYPT Stock to Your Portfolio Now | EyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Here's Why You Should Add EYPT Stock to Your Portfolio Now - TradingView | Here's Why You Should Add EYPT Stock to Your Portfolio Now TradingView | View source ↗ | TradingView | Oct 15, 2026 | neutral | 0 | 0.6 |
| RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week | Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.25 | 1 |
| RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week | Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.25 | 1 |
| Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance | Corcept Therapeutics Incorporat (CORT) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label | Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now | Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now | Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.25 | 1 |
| Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal | Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal | Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| BMY Reports Mixed Phase III Trial Results, Stock Down | Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| BMY Reports Mixed Phase III Trial Results, Stock Down | Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? | Options traders are pricing in significant volatility for Corcept Therapeutics, with the November 20, 2026 $47.50 Put showing high implied volatility. The company holds a Zacks Rank #1 (Strong Buy) rating, and analysts have raised earnings estimates over the past 60 days, with consensus moving from 55 cents to 68 cents per share. High implied volatility may indicate traders are positioning for a major price move or preparing to sell premium. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? | Options traders are pricing in significant volatility for Corcept Therapeutics, with the November 20, 2026 $47.50 Put showing high implied volatility. The company holds a Zacks Rank #1 (Strong Buy) rating, and analysts have raised earnings estimates over the past 60 days, with consensus moving from 55 cents to 68 cents per share. High implied volatility may indicate traders are positioning for a major price move or preparing to sell premium. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - TradingView | Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? TradingView | View source ↗ | TradingView | Oct 13, 2026 | neutral | 0 | 0.6 |
| Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why | Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.4 | 1 |
| PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know | PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.4 | 1 |
| CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits | CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally Stocktwits | View source ↗ | Stocktwits | Oct 10, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo! Finance Canada | Corcept Therapeutics Incorporat (CORT) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions - Simply Wall Street | Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| An officer reports 12,191 shares, including unvested awards, and four option positions at Corcept (CORT). - Stock Titan | An officer reports 12,191 shares, including unvested awards, and four option positions at Corcept (CORT). Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| 3 Reasons to Sell CORT and 1 Stock to Buy Instead - StockStory | 3 Reasons to Sell CORT and 1 Stock to Buy Instead StockStory | View source ↗ | StockStory | Oct 5, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics Stock Price Forecast. Should You Buy CORT? - StockInvest.us | Corcept Therapeutics Stock Price Forecast. Should You Buy CORT? StockInvest.us | View source ↗ | StockInvest.us | Oct 2, 2026 | neutral | 0 | 0.6 |
| After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. - Stock Titan | After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each - Stock Titan | Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Corcept (NASDAQ: CORT) director to sell 26,685 shares - Stock Titan | Corcept (NASDAQ: CORT) director to sell 26,685 shares Stock Titan | View source ↗ | Stock Titan | Aug 26, 2026 | neutral | 0 | 0.6 |
| $22M stock sale lined up at Corcept Therapeutics (NASDAQ: CORT) - Stock Titan | $22M stock sale lined up at Corcept Therapeutics (NASDAQ: CORT) Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics Stock Climbs 11% On A 6-Day Winning Streak - Trefis | Corcept Therapeutics Stock Climbs 11% On A 6-Day Winning Streak Trefis | View source ↗ | Trefis | Aug 24, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales - Yahoo Finance | Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales Yahoo Finance | View source ↗ | Yahoo Finance | Aug 7, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics (CORT) Stock Rises on Q2 2026 Earnings - Quiver Quantitative | Corcept Therapeutics (CORT) Stock Rises on Q2 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 29, 2026 | neutral | 0 | 0.6 |
| Why Corcept (CORT) Stock Is Down Today - Yahoo Finance | Why Corcept (CORT) Stock Is Down Today Yahoo Finance | View source ↗ | Yahoo Finance | Jul 27, 2026 | neutral | 0 | 0.6 |
| Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup - ChartMill | Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup ChartMill | View source ↗ | ChartMill | Jul 11, 2026 | neutral | 0 | 0.6 |
| CORT Stock Rises 42% in a Month: Here's What You Should Know - Yahoo Finance | CORT Stock Rises 42% in a Month: Here's What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Jun 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.